Doxorubicin and CpG loaded liposomal spherical nucleic acid for enhanced Cancer treatment

J Nanobiotechnology. 2022 Mar 18;20(1):140. doi: 10.1186/s12951-022-01353-5.

Abstract

Chemotherapeutics that can trigger immunogenic cell death (ICD) and release tumor-specific antigens are effective on treating a variety of cancers. The codelivery of chemotherapeutics with adjuvants is a promising strategy to achieve synergistic therapeutic effect. However, low drug loading and complicated preparation of current delivery systems lead to carrier-associated toxicity and immunogenicity. Herein, we developed a facile approach to construct liposomal spherical nucleic acids (SNA) by the self-assembly of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)-doxorubicin conjugate and DOPE-matrix metalloproteinases-9 (MMP-9) responsive peptide-CpG conjugate (DOPE-MMP-CpG). Liposomal SNAs efficiently co-delivered DOX and CpG into tumors and released the two drugs upon biological stimuli of MMP-9 enzyme in tumor microenvironment (TME) and high concentration of endogenous glutathione in tumor cells. We demonstrated that liposomal SNA enhanced activation of dendritic cells (DCs), promoted expansion of CD8+ and CD4+ T cells in both tumors and spleen, inhibited tumor growth, and extended animal survival. This work provided a simple strategy of delivering chemotherapeutics and adjuvants to tumors with synergistic therapeutic effect and reduced side effect.

Keywords: Cancer immunotherapy; Co-delivery; CpG; Nanoparticle; Triggered release.

MeSH terms

  • Animals
  • Doxorubicin / pharmacology
  • Liposomes
  • Neoplasms* / drug therapy
  • Nucleic Acids*
  • Tumor Microenvironment

Substances

  • Liposomes
  • Nucleic Acids
  • Doxorubicin